

others was prepared and sugar-coated. Expirations of volunteers given the tablet orally has no off-odor while those of volunteers given a control tablet containing no methylcobalamin had offensive odor.

***Inventor(s)***

Sato, Junichi; Kawada, Teruyuki; Makino, Tadashi

***Assignee(s)***

Takeda Chemical Industries Ltd, Japan

***Application Information***

JP 1995-204796 10 August, 1995

***Priority Information***

JP 1995-204796 10 August, 1995

***Patent Information***

Number	Kind	Date	Application	Date
JP 09052832	A2	25 February, 1997	JP 1995-204796	10 August, 1995

☐ 01 August 2003 at 15:01 - ANSWER 28 OF 52

HCAPLUS ©2003 ACS on STN  
1996:417857-Full Text

**Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound**

Patent Number WO 9611009 A1 18 April, 1996

PCT Int. Appl., 16 pp.

***Abstract***

The use of a combination of a tricyclic or tetracyclic antidepressant, a serotonin reuptake inhibitor, or a monoamine oxidase inhibitor with a neurotransmitter-inducing or precursor compound is proposed in the preparation of medication for the treatment or prevention of multiple sclerosis or other demyelinating conditions. For use in treatment to ameliorate the effects of a demyelinating condition, a daily regime is proposed of 10-220 mg lofepramine and from 100 mg to 5 g of L-phenylalanine, optionally supplemented with injections of vitamin B12. Case histories and composition examples are included.

***Inventor(s)***

Loder, Cari

***Assignee(s)***

UK

***Application Information***

WO 1995-GB2361 5 October, 1995

***Priority Information***

GB 1994-20116 A 5 October, 1994  
 GB 1995-8482 A 26 April, 1995  
 WO 1995-GB2361 W 5 October, 1995  
 US 1997-817086 A3 27 June, 1997

#### **Patent Information**

Number	Kind	Date	Application	Date
(1) WO 9611009	A1	18 April, 1996	WO 1995-GB2361	5 October, 1995
CA 2200761	AA	18 April, 1996	CA 1995-2200761	5 October, 1995
AU 9536126	A1	2 May, 1996	AU 1995-36126	5 October, 1995
AU 710339	B2	16 September, 1999		
GB 2308065	A1	18 June, 1997	GB 1997-7065	5 October, 1995
GB 2308065	B2	13 January, 1999		
EP 784476	A1	23 July, 1997	EP 1995-933488	5 October, 1995
(2) EP 784476	B1	6 November, 2002		
HU 77380	A2	28 April, 1998	HU 1997-2373	5 October, 1995
JP 10508583	T2	25 August, 1998	JP 1995-512415	5 October, 1995
ZA 9508391	A	6 May, 1999	ZA 1995-8391	5 October, 1995
SK 281932	B6	11 September, 2001	SK 1997-438	5 October, 1995
PL 181802	B1	28 September, 2001	PL 1995-319830	5 October, 1995
AT 227124	E	15 November, 2002	AT 1995-933488	5 October, 1995
ES 2184808	T3	16 April, 2003	ES 1995-933488	5 October, 1995
FI 9701290	A	2 June, 1997	FI 1997-1290	26 March, 1997
NO 9701539	A	4 April, 1997	NO 1997-1539	4 April, 1997
US 6096737	A	1 August, 2000	US 1997-817086	27 June, 1997
US 6569850	B1	27 May, 2003	US 2000-584401	1 June, 2000

(1) - W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT; RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

(2) - R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

☐ 01 August 2003 at 15:01 - ANSWER 29 OF 52

HCAPLUS ©2003 ACS on STN  
 1996:106491-Full Text

### **Cobalamins as nitric oxide sequestrants**

Patent Number WO 9531204 A1 23 November, 1995

PCT Int. Appl., 50 pp.

#### **Abstract**

NO is sequestered from the bloodstream, endothelium, or tissues of mammals by administering a cobalamin (5-50 mg/kg) for treatment of diseases characterized by elevated NO levels. In particular, methods of treating sepsis and of alleviating systemic hypotension in a septic patient by administering a therapeutic dose of hydroxocobalamin are described. Thus, hydroxocobalamin reversed the hypotension and reduced the mortality resulting from injection of lipopolysaccharide into rats; simultaneously, hydroxocobalamin decreased plasma levels and increased urinary levels of the NO metabolites, NO<sub>2</sub>- and NO<sub>3</sub>-.

#### **Inventor(s)**

Greenberg, Stanley S.; Xie, Jianming; Miller, Mark J. S.; Zatarian-Kuebel, Judy